MTSL Issue 851

 Comments Off on MTSL Issue 851
May 072017
 
MTSL Issue 851

MTSL Issue 851 (dated 5/04/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #BMRN #CELG #ESPR #FPRX #INCY #IONS #MDCO #PCRX #SGMO #ZIOP

MTSL Issue 847

 Comments Off on MTSL Issue 847
Mar 052017
 
MTSL Issue 847

MTSL Issue 847 (dated 3/02/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #BMRN #CELG #FPRX #INCY #XON #IONS #MDCO #NKTR #PCRX #SGMO

MTSL Issue 844

 Comments Off on MTSL Issue 844
Jan 222017
 
MTSL Issue 844

MTSL Issue 844 (dated 1/19/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #BMRN #CELG #INCY #IONS #MDCO #NKTR #PCRX #SGMO #ZIOP

10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)

 Comments Off on 10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)
Nov 292016
 
10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16)

November 17, 2016 Opinion : 10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16) The Republican sweep of Washington has generated a ton of enthusiasm for biotech stocks. They’re up 10% to 15% since the elections. As a result, biotech analysts’ phones are ringing off the hook again after a depressingly bleak […]

Celgene Update (2-21-13)

 Comments Off on Celgene Update (2-21-13)
Feb 212013
 
Celgene Update (2-21-13)

“Celgene Announces Accelerated $600 Million Share Repurchase Program” In a clear sign of optimism about its corporate outlook, CELG today announced it would accelerated share repurchases of $600 million of the company’s common stock, representing approximately 1.4% of shares outstanding. The long-awaited PFS data for the Revlimid MM-020 trial is due end-Q2/early Q3.

Celgene Update (2-09-13)

 Comments Off on Celgene Update (2-09-13)
Feb 092013
 
Celgene Update (2-09-13)

Pomalyst (“Pom”) was approved by the FDA for the treatment of multiple myeloma (MM) patients who have failed two prior therapies, providing the beginning of another growth driver for CELG. The Fast Track approval was based on response rates.

Celgene Update (1-18-13)

 Comments Off on Celgene Update (1-18-13)
Jan 182013
 
Celgene Update (1-18-13)

OUTLOOK 2013, RAISING BUY LIMIT AND TARGET PRICE As recently as the summer of 2012, Celgene had a stable but slowing core business led by Revlimid but no apparent pipeline.  Questions arose about the company’s long-term growth. In a remarkable turn of events, the company and stock have been revived by not one but three […]

Celgene Update (11-16-12)

 Comments Off on Celgene Update (11-16-12)
Nov 162012
 
Celgene Update (11-16-12)

Celgene’s stock is up since the last Issue on good news. The company announced that Abraxane has achieved overall survival (OS) is Phase III trial treating metastatic pancreatic cancer patients.  CELG did not provide any exact results as they plan to present the data at an upcoming scientific meeting. We do know that the company designed […]

Celgene Update (10-19-12)

 Comments Off on Celgene Update (10-19-12)
Oct 192012
 
Celgene Update (10-19-12)

Celgene’s stock is down since the last Issue as it also corrected this Friday. This week, additional information became available on the FDA’s website regarding the cancellation of the November 8th ODAC meeting originally scheduled to discuss pomalidomide.